SECURITIES AND EXCHANGE COMMISSION
                                    
                          Washington, DC  20549
                                    
                                    
                                FORM 8-K
                                    
                                    
                                    
  CURRENT REPORT     
  
                            
                            
                            Pursuant to Se       ction 13 or 15(d) of the
  Securities Exc           hange Act of 1934
  
                            
                            
                            
                            August 25, 199                   4
  
                            
                            
                            
                            Mallinckrodt G               roup Inc.
  (Exact name of registrant as specified in its charter)
  
                            
                            
                            
  New York            1-483
               36-1263901
  (State or other jurisdiction          (Commission             (IRS
  Employer
          of incorporation)                    File Number)       
        Identification No.)
  
  
  7733 Forsyth Boulevard, St. Louis, MO           63105-1820
  (Address of principal executive offices)              (Zip
  Code)
  
  Registrant's telephone number,                       (314)
  854-5200
           including area code
  MALLINCKRODT GROUP ANNOUNCES PLANS TO REPURCHASE STOCK
  Item 5
  ST. LOUIS, August 25, 1994 -- Mallinckrodt Group Inc.
  (NYSE:MKG) today announced it will purchase up to two million
  shares of the company's common stock over an unspecified period
  of time as market conditions warrant.  The shares will be
  bought on the open market.
     C. Ray Holman, president and chief executive officer, said
  "Our Board of Directors and management have tremendous
  confidence in the future of this company.  A share repurchase
  program reinforces that confidence and confirms our belief that
  our stock is a good investment opportunity."
     The current share repurchase plan falls under an October
  1988 authorization for the purchase of up to 42 million shares
  of the company's common stock.  Since that time, about 29
  million shares have been purchased by the company, leaving
  approximately 13 million shares in the 1988 purchase
  authorization.
     Commenting on the fiscal year ended June 30, Holman said,
  "We were pleased with the 24 percent increase in earnings over
  the previous year to $287 million, prior to the previously
  announced restructuring charge, and net sales of $1.94 billion,
  which was an 8 percent increase over 1993."
     "We also were encouraged by a number of positive events
  that occurred during fiscal 1994.  The company made two
  important acquisitions -- DAR, a leading Italian manufacturer
  of anesthesiology and respiratory products, and Catalyst
  Resources, Inc., purchased from Phillips Petroleum.  Catalyst
  Resources is expected to double Mallinckrodt Chemical's
  catalyst business, and DAR gives Mallinckrodt Medical an
  expanded international presence and a platform for further
  growth in an area where many of our products already are market
  leaders," Holman said.
     "The U.S. Food and Drug Administration's mid-June approval
  of OctreoScan, a radiopharmaceutical for diagnosing certain
  cancer tumors, and early August authorization of Albunex, the
  first contrast media for use with ultrasound, were also good
  news in terms of outlook for the future.  Both products have
  the potential to generate significant revenues," he added.  "In
  addition, our recently signed agreement with Boehringer
  Ingelheim Animal Health, Inc., under which Mallinckrodt
  Veterinary will begin private-label marketing and distribution
  of certain Boehringer Ingelheim cattle respiratory vaccines in
  the United States immediately, marks the second notable step in
  our strategy to develop global leadership in biologicals, the
  fastest growing segment of the animal health industry.  During
  fiscal 1994, we broke ground for a new world-class biological
  facility in Raleigh, North Carolina."
     "With these, and other major events anticipated in fiscal
  1995, we are confident about our commitment to the aggressive
  growth and profit targets we have set."  Holman said the
  company is committed to achieving compounded annual sales
  growth of 10 to 12 percent and earnings growth of at least 15
  percent through 1999.
     Mallinckrodt Group Inc., a Fortune 250 company, had net
  sales of $1.94 billion in fiscal 1994.  Headquartered in St.
  Louis, Missouri, the company provides human and animal health
  products and specialty chemicals through its three
  international technology-based businesses -- Mallinckrodt
  Chemical and Mallinckrodt Medical, both headquartered in St.
  Louis, Missouri and Mallinckrodt Veterinary, headquartered in
  Mundelein, Illinois.  Mallinckrodt Group and its subsidiaries
  have approximately 10,000 employees worldwide.